–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4 of 2025– –The Company raised approximately $100 million in an oversubscribed public offering of common stock, which is expected to fund advancement of the BB-301 Oculopharyngeal Muscular Dystrophy (OMPD) registrational program and associated regulatory filing activities– HAYWARD, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma...

SAN JOSE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended September 30, 2025. As of September 30, 2025, the Fund’s net assets were $296,547, or $0.04 per share, compared with net assets of approximately $0.7 million, or $0.11 per share as of June 30, 2025. As of September 30, 2025, the Fund’s portfolio included public and private securities valued at $256,934, or $0.04 per share, which includes approximately $0.01 per share in cash and cash equivalents. Portfolio Summary (as of 9/30/25)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $197,925 $0.03Cash/Cash Equivalents $59,009 $0.01Other...

Second quarter results highlight improved cost management capital structure enhancements DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today reported its financial results for the fiscal 2026 second quarter, which ended September 30, 2025. Commenting on the fiscal 2026 second quarter results, interim Chief Executive Officer James Silk said: “The second quarter results demonstrate our disciplined approach to managing both our investment portfolio and operating expenses during a pivotal period for Beneficient. We reduced expenses, completed new primary capital transactions, generated additional liquidity through asset sales...

Total Revenue of $77.7 million, an increase of approximately 15% quarter-over-quarter Net Income of $1.3 million Record Adjusted EBITDA of $56.3 million, an increase of over 45% quarter-over-quarter Approximately 10% increase in quarterly production to a total of 23,029 Boe/d per day (52% oil / 72% liquids) Current production rate of approximately 27,000 net Boe/d per dayHOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company,” “Prairie,” “we,” “our,” or “us”) – an independent energy company engaged in the development and acquisition of oil, natural gas, and natural gas liquids (“NGL”) resources in the Denver-Julesburg (DJ) Basin – today announced its financial and operational results through and subsequent to the quarter ended September 30, 2025. RECENT KEY HIGHLIGHTSRecord total production...

Company to host investor conference call and webcast on Monday, November 17th, at 9:00am EST PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights:Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional...

CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident” or the “Company”) (TSX:PPR) announces its financial and operating results for the third quarter of 2025. The Company’s interim financial statements for the three and nine months ended September 30, 2025 and related Management’s Discussion and Analysis (“MD&A”) are available on our website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca. THIRD QUARTER 2025 FINANCIAL AND OPERATING HIGHLIGHTSProduction averaged 2,295 boe/d (57% liquids)1 for Q3 2025, which was 6% or 122 boe/d higher than Q3 2024, due to the increased Basal Quartz production. Q3 2025 operating expenses were $30.39 boe/d, an increase of 13% or $3.46 per boe/d from Q3 2024, principally due to higher spending with respect to chemicals,...

LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) — XMax Inc. (“Xmax” or the “Company”) (NASDAQ: XWIN), today announced its unaudited financial results for the three months ended September 30, 2025. Operating Results for the Three Months ended September 30, 2025Net Sales grew by 273% to $9.76 million from $2.62 million in the same period of 2024. Gross profit was $0.98 million, compared to $1.18 million in the same period of 2024. Net loss was $1.13 million, compared to a net loss of $2.47 million in the same period of 2024.Operating Results for the Nine Months Ended September 30, 2025:Net Sales grew by 95% to $14.95 million from $7.68 million in the same period of 2024. Gross profit was $3.47 million, compared to $3.39 million in the same period of 2024. Net loss was $1.76 million, compared to a net loss...

MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2025. The Company anticipates dosing the first patient in a Phase 1 clinical study (NCT07049328) to evaluate HCW9302 in patients with an autoimmune disease in the fourth quarter of 2025. HCW9302 is the Company’s lead product candidate for its clinical program to develop treatments for autoimmune diseases and inflammatory conditions. HCW9302 is a subcutaneously injectable, first-in-kind interleukin 2 (“IL-2”) fusion molecule constructed...